Literature DB >> 18808560

Informed consent and medical ordeal: a qualitative study.

M Little1, C F C Jordens, C McGrath, K Montgomery, W Lipworth, I Kerridge.   

Abstract

BACKGROUND: Informed consent is a mainstay of clinical practice, with both moral and legal forces. Material disclosure about extreme treatments, however, is unlikely to convey the full impact of the experience of treatment. Informed consent may be flawed under such circumstances. The aims of this study were to compare expressed satisfaction with pretreatment information to satisfaction after experiencing autologous stem cell transplantation for recurrent lymphoma.
METHODS: A qualitative, narrative-based cohort study was conducted in a bone-marrow transplant unit of a teaching hospital at Westmead Hospital, Sydney, Australia. The cohort consisted of 10 transplant recipients and 9 of their nominated lay carers. The outcome measure was satisfaction expressed in narrative interviews at the time of transplantation and 3 months later. We used discourse-analytic techniques to examine the narratives.
RESULTS: Both patients and carers expressed high satisfaction with the information given by individual clinicians and by speakers at a formal Information Day held before transplantation. At the first interview, neither patients nor carers commented much on the forthcoming ordeal of chemotherapy and bone marrow ablation, although all patients had undergone previous chemotherapy. At the second interview, the ordeal dominated the narratives and retrospective dissatisfaction with information was common.
CONCLUSION: This study suggests that information about treatment theories and protocols can be satisfactorily communicated, but personal experience of suffering defies communication. This finding has serious implications for the practices involved in obtaining informed consent and for the very notion of informed consent.

Entities:  

Mesh:

Year:  2008        PMID: 18808560     DOI: 10.1111/j.1445-5994.2008.01700.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  8 in total

1.  Trouble in the gap: a bioethical and sociological analysis of informed consent for high-risk medical procedures.

Authors:  Christopher F C Jordens; Kathleen Montgomery; Rowena Forsyth
Journal:  J Bioeth Inq       Date:  2013-01-04       Impact factor: 1.352

2.  "I had already made up my mind": patients and caregivers' perspectives on making the decision to participate in research at a US cancer referral center.

Authors:  Kathleen Shannon-Dorcy; Denise J Drevdahl
Journal:  Cancer Nurs       Date:  2011 Nov-Dec       Impact factor: 2.592

Review 3.  Patient and Caregiver Adjustment to Hematopoietic Stem Cell Transplantation: a Systematic Review of Dyad-Based Studies.

Authors:  Shelby Langer; Christine Lehane; Jean Yi
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

Review 4.  Is 'informed consent' an 'understood consent' in hematopoietic cell transplantation?

Authors:  A D'Souza; M Pasquini; R Spellecy
Journal:  Bone Marrow Transplant       Date:  2014-09-22       Impact factor: 5.483

5.  Informed consent and fresh egg donation for stem cell research.

Authors:  Katherine Carroll; Catherine Waldby
Journal:  J Bioeth Inq       Date:  2011-12-23       Impact factor: 1.352

6.  Quality of informed consent for invasive procedures in central Saudi Arabia.

Authors:  Mostafa A Abolfotouh; Abdallah A Adlan
Journal:  Int J Gen Med       Date:  2012-03-20

7.  Development of a Patient Reported Measure of Experimental Transplants with HIV and Ethics in the United States (PROMETHEUS).

Authors:  Shanti Seaman; Diane Brown; Ann Eno; Sile Yu; Allan B Massie; Aaron A R Tobian; Christine M Durand; Dorry L Segev; Albert W Wu; Jeremy Sugarman
Journal:  J Patient Rep Outcomes       Date:  2021-03-18

8.  Patient and Provider Perspectives on the Impacts of Unpredictability for Patient Sensemaking: Implications for Intervention Design.

Authors:  Sarah Fadem; Lisa Mikesell
Journal:  J Patient Exp       Date:  2022-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.